Cantor Fitzgerald Reiterates Overweight Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Cantor Fitzgerald reiterated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Tuesday, Benzinga reports. They currently have a $13.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 18th. Oppenheimer raised Marinus Pharmaceuticals from a market perform rating to an outperform rating and set a $6.00 price target for the company in a research note on Monday, September 23rd. JMP Securities reaffirmed a market outperform rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Monday, September 23rd. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Finally, Truist Financial restated a buy rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of Hold and a consensus price target of $8.83.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $1.84 on Tuesday. The stock has a market cap of $101.08 million, a PE ratio of -0.70 and a beta of 1.13. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The business’s 50-day simple moving average is $1.40 and its two-hundred day simple moving average is $2.67. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same period in the prior year, the firm posted ($0.61) earnings per share. As a group, analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $28,000. SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $34,000. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at $64,000. Finally, Values First Advisors Inc. grew its position in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.